Trastuzumab - an overview

trastuzumab  Trastuzumab has also been shown to penetrate an impaired blood–brain barrier to a limited degree, such as during radiotherapy, and intrathecal delivery of trastuzumab Early breast cancer Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery

In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed  Key Message The ShortHER trial failed to demonstrate the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy The short

If you're having trastuzumab to treat primary breast cancer after surgery, it's usually given for 1 year Some people may be offered Trastuzumab deruxtecan may cause hair loss Any hair loss caused should be temporary and in most cases your hair will begin to grow back once your treatment has